Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of KZR-616 in Polymyositis or Dermatomyositis
2020-004382-39Phase 2Completed
- Sponsor
- Kezar Life Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zetomipzomib in polymyositis (PM), dermatomyositis (DM) and autoimmune disease, sponsored by Kezar Life Sciences. Primary endpoint: Long-term efficacy of KZR-616. Started Jan 2022; status: completed.
02
Drugs
zetomipzomib
03
Conditions
polymyositis (PM)dermatomyositis (DM)autoimmune disease
Beyond the preview
Go deeper on 2020-004382-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004382-39.